Kappos L - Search Results

1

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Wolinsky JS, et al. Among authors: kappos l. Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. Mult Scler. 2013. PMID: 23447359 Free article. Clinical Trial.

2

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Miller DH, et al. Among authors: kappos l. J Neurol Neurosurg Psychiatry. 1991 Aug;54(8):683-8. doi: 10.1136/jnnp.54.8.683. J Neurol Neurosurg Psychiatry. 1991. PMID: 1940938 Free PMC article.

3

Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C. Polman CH, et al. Among authors: kappos l. Mult Scler. 1995;1 Suppl 1:S51-4. Mult Scler. 1995. PMID: 9345400 Clinical Trial.

4

Combinations of drugs.

Kappos L. Kappos L. Mult Scler. 1996 Jul;1(6):400-3. doi: 10.1177/135245859600100624. Mult Scler. 1996. PMID: 9345426

5

The contribution of magnetic resonance imaging in the differential diagnosis of the damage of the cerebral hemispheres.

Grossman RI, Kappos L, Wolinsky JS. Grossman RI, et al. Among authors: kappos l. J Neurol Sci. 2000 Jan 15;172 Suppl 1:S57-62. doi: 10.1016/s0022-510x(99)00281-6. J Neurol Sci. 2000. PMID: 10606809 Free article. Review.

6

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Kappos L, et al. Nat Med. 2000 Oct;6(10):1176-82. doi: 10.1038/80525. Nat Med. 2000. PMID: 11017151 Clinical Trial.

7

Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.

Constantinescu CS, Freitag P, Kappos L. Constantinescu CS, et al. Among authors: kappos l. Mult Scler. 2000 Dec;6(6):378-81. doi: 10.1177/135245850000600603. Mult Scler. 2000. PMID: 11212132 Clinical Trial.

8

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Polman C, et al. Among authors: kappos l. Mult Scler. 2003 Aug;9(4):342-8. doi: 10.1191/1352458503ms923oa. Mult Scler. 2003. PMID: 12926838 Clinical Trial.

9

Interferon-beta antibodies: implications for the treatment of MS.

Wolinsky JS, Toyka KV, Kappos L, Grossberg SE. Wolinsky JS, et al. Among authors: kappos l. Lancet Neurol. 2003 Sep;2(9):528. doi: 10.1016/s1474-4422(03)00499-x. Lancet Neurol. 2003. PMID: 12941572 Review. No abstract available.

10

Towards a european network for multiple sclerosis trials (ENMST).

Kappos L, Polman C, Thompson AJ, Duda P, Clanet M, Comi G, Hartung HP, Montalban X. Kappos L, et al. Mult Scler. 2003 Dec;9(6):627-9. doi: 10.1191/1352458503ms962xx. Mult Scler. 2003. PMID: 14664478

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

815 results

Search Page

Filters